Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise
LONDON, Sept. 30, 2026 /PRNewswire/ — Clarenta today announced that Leads To Development (L2D) has joined Clarenta Group following a majority investment, strengthening Clarenta’s ability to support biotech and pharmaceutical sponsors from
